Nova Eye USA Sales Growth Opportunity

1) 2) Use of Proceeds $3.7m Glaucoma Surgical Devices:$7.0m USA sales growth - USA sales representative expansion, marketing and clinical data program enhancement $1.6m Outside USA sales growth - Expand commercial infrastructure in prospective markets to leverage investment in market access $1.7m Broaden product portfolio and regulatory approvals to de-risk reimbursement changes (1) Other Costs: $0.5m $0.5m MDR(2) compliance and working capital Offer Costs: $0.5m $0.5m Costs of the Offer Total: $8.0m iTrack Next Gen only. Molteno Next Gen investment subject to cash generated from operations Medical Device Regulation in Europe nova-eye.com | 22

View entire presentation